Abstract
Collaboration between patient advocacy and industry to create a master protocol to investigate the novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosides and ataxia-telangiectasia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have